Platelet aggregation independent of ADP release or prostaglandin synthesis in patients with hermansky-Pudlak syndrome.
Platelets from patients with the Hermansky-Pudlak (HPS) syndrome are deficient in the storage pool of adenine nucleotides and serotonin. As a result, the storage pool deficient (SPD) platelets develop only single waves of clumping when stimulated by threshold concentrations of aggregating agents which cause irreversible, biphasic aggregation of normal platelets. Yet, patients with HPS either have no bleeding problems or only mild symptoms. In the present study we have evaluated the importance of prostaglandin synthesis and secretion to the irreversible aggregation of HPS platelets. Results of the study demonstrate that aspirin-treated SPD platelets, which cannot form thromboxane or undergo the release reaction on stimulation by arachidonate, can still undergo irreversible aggregation in response to thrombin and ADP if treated first with epinephrine. A mechanism of membrane modulation mediated by alpha-adrenergic receptors cooperatively linked to the endoperoxide and thromboxane receptor can secure irreversible aggregation of normal or abnormal platelets despite absence of secretion and prostaglandin synthesis.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000417:Albinism / Q000097:blood*; D001095:Arachidonic Acids / Q000097:blood; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000502:physiology; D004837:Epinephrine / Q000494:pharmacology; D006474:Hemorrhagic Disorders / Q000097:blood*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000502:physiology*; D013917:Thrombin / Q000494:pharmacology; D013931:Thromboxanes / Q000097:blood
D001095:Arachidonic Acids; D011453:Prostaglandins; D013931:Thromboxanes; D000244:Adenosine Diphosphate; D013917:Thrombin; D001241:Aspirin; D004837:Epinephrine